SELLAS Life Sciences develops licensed cancer drugs, led by the galinpepimut-S (GPS) vaccine for acute myeloid leukaemia and the kinase inhibitor tambiciclib (SLS009).
Implied return -54% to our target. Bear to bull $0.18 to $26.77, from our initiation of Nov 19, 2026. We expect a total return worse than −10% over the next 12 months: a fall of more than 10%, after dividends.
Sum-of-programmes risk-adjusted NPV at an 11.06% cost of equity with zero terminal value: GPS CR2 ($3.03), GPS CR1 ($2.49) and SLS009 ($0.39) less corporate costs and tax, plus net cash, offering and future raises, gives a $4.97 base on 230.9m diluted shares. Bear, base and bull values of $0.18, $4.97 and $26.77 are weighted 30/50/20% to $7.90 and rolled forward 12 months to the $8.77 target. A 2.3x FY30E peer sales exit gives $4.11.